Compass utilizes social media for rare disease

Share this article:
BioMarin Pharmaceuticals has tasked Compass Healthcare with the redesign of its unbranded Phenylketonuria (PKU) community website, www.PKU.com. The new site is slated to launch during Q2 2009.

In order to reach the roughly 12,000 individuals diagnosed with PKU in the US, Compass hopes to foster online engagement within the PKU community. The new site will allow registered members to maintain blogs and create other content. Static content created by BioMarin is subject to review by a panel of community members, according to Kristin Keller, VP, client services, at Compass. The site will also offer recipes and a diet food wiki, notes Keller. 

PKU is a genetic condition that prohibits the body from metabolizing phenylalanine (Phe), an amino acid. 
PKU sufferers must avoid foods high in protein. 

“The purpose of the PKU.com site is to provide the PKU community with support and resources to better manage their disease,” said Keller. 

BioMarin markets Kuvan, a prescription treatment that lowers Phe levels in the bloodstream.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.